pre-miRNA Information
pre-miRNA hsa-mir-628   
Genomic Coordinates chr15: 55372940 - 55373034
Synonyms MIRN628, hsa-mir-628, MIR628
Description Homo sapiens miR-628 stem-loop
Comment The mature sequence shown here represents the most commonly cloned form from large-scale cloning studies .
RNA Secondary Structure
Associated Diseases

Mature miRNA Information
Mature miRNA hsa-miR-628-3p
Sequence 61| UCUAGUAAGAGUGGCAGUCGA |81
Evidence Experimental
Experiments Microarray
Editing Events in miRNAs
Modification Type Position on miR Chromosome DNA Strand Genomic Position (hg38) List of PMIDs Variant details
A-to-I 7 15 - 55372968 29233923 MiREDiBase
A-to-I 8 15 - 55372967 29233923 MiREDiBase
C-to-U 19 15 - 55372956 20591823 MiREDiBase
DRVs in miRNA
Mutant ID Mutant Position Mutant Source
COSN26969715 1 COSMIC
COSN30123186 10 COSMIC
SNPs in miRNA
Mutant ID Mutant Position Mutant Source
rs1410255602 2 dbSNP
rs1401315366 3 dbSNP
rs1322836365 4 dbSNP
rs1158103480 8 dbSNP
rs1216611749 11 dbSNP
rs749619551 13 dbSNP
rs778157225 18 dbSNP
rs756600789 19 dbSNP
Putative Targets

miRNA Expression profile
Human miRNA Tissue Atlas
miRNAs in Extracellular Vesicles
Circulating MicroRNA Expression Profiling
Gene Information
Gene Symbol ABT1   
Synonyms Esf2, hABT1
Description activator of basal transcription 1
Transcript NM_013375   
Expression
Putative miRNA Targets on ABT1
3'UTR of ABT1
(miRNA target sites are highlighted)
>ABT1|NM_013375|3'UTR
   1 GGGCCTGGGTGGCCCCTTCCATTTCCTGGCCCTGCTCTGCTTCCTGTCTACCTCATACTAGAATGATCGTGACTACCCGG
  81 GCAGACATTTTACTGTGTTTCTCAGACCAAGTGTCTACTGATGGCCCAAACATGGAGTTTTGTGGGCTTCCACTGTCCCC
 161 ACTCCGAACTCCTGTATGTGCCTGGCTGAGTCACCTAATTCATACTGTCATACTAGCATAATTATGACTATTGCATATGC
 241 TTGTTTTGTTTGACTCTTGGCTGCCTACGTCTGTAGGGTCCCCTGAAAATCCCACTTCCTGCCCCCAGAAAGGGCCTTTA
 321 TTTCCAACTAGGAGGATAATGCCTAGTCCAGGCAATCTTTCTCTGTTTAGCAGTCACAGGTGAGGGTGGTATTAGCATCT
 401 TTTTTATGTAGAAAAAATTGAGTTAATGGGGTGGACTGGGTTGGGAAGAAATACATTTCCTAATGTATTTATAGAAAATA
 481 AAAATATTTTTATGTGCCTTTTTATTTTTGTTGGTGGGGAGGTCATTGGACAAGTTCCAACTTTCATCTTGTGTTCCCTT
 561 CACCTTCATATCCTGATCTTAGAGCCCCCCTCCCCCTGCCACCCACCTTACTGTTTAACCTGGATTTTTTTTTCTATTTA
 641 ATTTTTGTCTAATATCTTAGCCCAGTTTATCAATCAGTTATCTTAAGTCAGCATTTTCTAAGCCATTGTTTGAGGAAACA
 721 GTGACAATAGGTAATAACACATCTTAGTATTAAGAGTTTTACAGGCCACTAGTATAAGATAGGCATCGTGGTAGATGCAT
 801 ATAAAGGGTGGAATGGGAGCCATGGCAGGTCATAGAGTCCTCTCAATGGGAACCTGATTGATGATCACAGTCTTCAGTGG
 881 TGAGTCAGTCCTCACCAAGTTTTCCAGATCATTCCTACAAAGTAAACTGGGAGAATAATAAGTCTGAAAGAGTGTGGAGT
 961 GCTCCCACAATTACAAAGAATGCTTCCTGGGTGGAGTGTTGAGTTGGAACCATTGTAAAGGTGGGCAAAGCCTAGTAGAG
1041 AACCAGTGCACCTCAGGTGCACTTACATATGGTGGGGCTGAGGCAAAGCAGCCCTGTAGGCTTCAAAGAATCAGTGTAAG
1121 CCACTAAAAGGAACTGAAAACCTAGGTGTCACAATAAACAGTCTACACAGTCTCACGTAGACCAAAATTCTGATCATTTT
1201 CCAGGCTGTTGCATGAAGTGATAGAGTATGATTATAATTTCTGTTTGCTTGTGCTGTTTGTTTTTGTTTTTCATCTGTCA
1281 ATGTGATGATCTGTGTTTTATAGGGTAGAGTGGATTTGTCTACTTTGGCTGTAAAATACCCTAATCACATTATGATCTTG
1361 ACAGGTGCACTTTACTGGGGAGAATAAAAAGGACCATACGGTAAA
Target sites Provided by authors   Predicted by miRanda    DRVs    SNPs    DRVs & SNPs
miRNA-target interactions
(Predicted by miRanda)
ID Duplex structure Position Score MFE
1
miRNA  3' agCUG---ACGGUGAGAAUGAUCu 5'
            |||   || |||| |||||:| 
Target 5' ttGACAGGTG-CACT-TTACTGGg 3'
1358 - 1379 141.00 -15.30
2
miRNA  3' agcuGAC-GGU-GAGAAUGAUCu 5'
              ||| |:| ||| |||||| 
Target 5' cttcCTGTCTACCTCATACTAGa 3'
40 - 62 133.00 -16.30
3
miRNA  3' agcUGACGGUGAGAAUGAUCu 5'
             ||||:||    |||||| 
Target 5' catACTGTCA----TACTAGc 3'
201 - 217 131.00 -12.10
DRVs in gene 3'UTRs
Mutant ID Mutant Position Mutant Source
COSN30509338 12 COSMIC
COSN30181703 45 COSMIC
COSN31612421 70 COSMIC
COSN16052739 81 COSMIC
COSN31511344 106 COSMIC
COSN2157913 121 COSMIC
COSN17038394 257 COSMIC
COSN29760004 634 COSMIC
COSN24955289 894 COSMIC
COSN17213110 905 COSMIC
COSN19078282 1636 COSMIC
COSN28324463 2044 COSMIC
rs45527431 637 GWAS
SNPs in gene 3'UTRs
Mutant ID Mutant Position Mutant Source
rs782597707 1 dbSNP
rs782219372 3 dbSNP
rs782367374 9 dbSNP
rs1374471119 11 dbSNP
rs781943753 13 dbSNP
rs782640242 14 dbSNP
rs1415022785 15 dbSNP
rs782273176 16 dbSNP
rs782818204 22 dbSNP
rs751550122 26 dbSNP
rs1170842854 28 dbSNP
rs782207883 37 dbSNP
rs563612129 38 dbSNP
rs370138971 47 dbSNP
rs1013441137 51 dbSNP
rs757553823 57 dbSNP
rs1438203874 68 dbSNP
rs1245406378 70 dbSNP
rs1188814626 74 dbSNP
rs1023437077 77 dbSNP
rs7773587 78 dbSNP
rs1277149684 79 dbSNP
rs1198176268 86 dbSNP
rs969717843 87 dbSNP
rs1352228461 88 dbSNP
rs186218450 97 dbSNP
rs1032461635 100 dbSNP
rs1351208512 109 dbSNP
rs562987068 122 dbSNP
rs1316840696 130 dbSNP
rs1339745093 133 dbSNP
rs1332120502 134 dbSNP
rs1383988127 166 dbSNP
rs1361311884 167 dbSNP
rs1158247329 168 dbSNP
rs13978 171 dbSNP
rs1387353091 174 dbSNP
rs1164151758 198 dbSNP
rs541955319 211 dbSNP
rs1236166394 224 dbSNP
rs1196039145 226 dbSNP
rs1488977467 227 dbSNP
rs1263335807 229 dbSNP
rs987875642 236 dbSNP
rs923043058 238 dbSNP
rs561718545 253 dbSNP
rs1293507454 261 dbSNP
rs954433446 267 dbSNP
rs1228607416 269 dbSNP
rs1355462610 270 dbSNP
rs1229580666 280 dbSNP
rs1341174657 282 dbSNP
rs1297610494 289 dbSNP
rs1398256544 291 dbSNP
rs13227 292 dbSNP
rs1367623539 296 dbSNP
rs1324464831 299 dbSNP
rs986272729 303 dbSNP
rs1405140959 307 dbSNP
rs1412152989 314 dbSNP
rs1170127082 317 dbSNP
rs1478458720 317 dbSNP
rs1423567103 318 dbSNP
rs1192228378 325 dbSNP
rs1487024591 329 dbSNP
rs1248089613 333 dbSNP
rs527681003 347 dbSNP
rs750673356 353 dbSNP
rs546449352 355 dbSNP
rs529249489 356 dbSNP
rs189939133 358 dbSNP
rs1450794878 359 dbSNP
rs73739030 360 dbSNP
rs552324058 364 dbSNP
rs919277896 369 dbSNP
rs1277508416 371 dbSNP
rs1216806751 378 dbSNP
rs1347543451 383 dbSNP
rs1275647998 387 dbSNP
rs1436090550 390 dbSNP
rs368622746 400 dbSNP
rs1331249295 403 dbSNP
rs1466482087 409 dbSNP
rs1400121259 410 dbSNP
rs1169246772 411 dbSNP
rs929271395 416 dbSNP
rs568989334 432 dbSNP
rs1191380679 434 dbSNP
rs1057130031 444 dbSNP
rs895914694 453 dbSNP
rs1477467614 456 dbSNP
rs369983822 461 dbSNP
rs1012971126 463 dbSNP
rs1458050412 475 dbSNP
rs1045302585 485 dbSNP
rs1196734475 486 dbSNP
rs1314006244 497 dbSNP
rs1218754556 499 dbSNP
rs905022628 499 dbSNP
rs1365681724 501 dbSNP
rs1281492090 512 dbSNP
rs781842144 515 dbSNP
rs1376696934 518 dbSNP
rs1329880315 527 dbSNP
rs1471265507 534 dbSNP
rs1001223960 541 dbSNP
rs1360278393 560 dbSNP
rs1176091833 566 dbSNP
rs1413425387 570 dbSNP
rs537913519 571 dbSNP
rs1032243080 579 dbSNP
rs1422540066 585 dbSNP
rs1180196448 587 dbSNP
rs1176671337 596 dbSNP
rs1440061987 596 dbSNP
rs1484173558 599 dbSNP
rs1238008592 604 dbSNP
rs554729175 605 dbSNP
rs1209422432 607 dbSNP
rs1310583518 608 dbSNP
rs1288405636 614 dbSNP
rs956599204 620 dbSNP
rs1241205464 625 dbSNP
rs1353399537 625 dbSNP
rs1009202227 635 dbSNP
rs45527431 637 dbSNP
rs782659382 650 dbSNP
rs1380453039 660 dbSNP
rs1302782362 664 dbSNP
rs551893680 677 dbSNP
rs1356989702 678 dbSNP
rs533782293 688 dbSNP
rs954465850 694 dbSNP
rs553844288 704 dbSNP
rs910747101 706 dbSNP
rs1156565057 707 dbSNP
rs1425338037 726 dbSNP
rs1414438013 727 dbSNP
rs1482302729 729 dbSNP
rs180692287 734 dbSNP
rs1488057404 746 dbSNP
rs186130957 763 dbSNP
rs974085340 764 dbSNP
rs1247357702 781 dbSNP
rs1322769768 782 dbSNP
rs556703191 811 dbSNP
rs1352992234 812 dbSNP
rs1299457215 813 dbSNP
rs189883839 827 dbSNP
rs1400107372 833 dbSNP
rs929513970 847 dbSNP
rs45568331 860 dbSNP
rs1286823524 868 dbSNP
rs917214516 869 dbSNP
rs948821045 893 dbSNP
rs1044477991 900 dbSNP
rs1163946291 906 dbSNP
rs905049803 918 dbSNP
rs1425716354 926 dbSNP
rs541873370 930 dbSNP
rs1194403295 934 dbSNP
rs1477538365 936 dbSNP
rs45600933 937 dbSNP
rs1054002270 939 dbSNP
rs892392129 944 dbSNP
rs1009401863 952 dbSNP
rs1265269533 952 dbSNP
rs141149859 958 dbSNP
rs1279407639 959 dbSNP
rs1218644154 963 dbSNP
rs954373211 968 dbSNP
rs555612859 971 dbSNP
rs11755959 983 dbSNP
rs1391043042 984 dbSNP
rs963432668 1002 dbSNP
rs1459689902 1004 dbSNP
rs1402284903 1005 dbSNP
rs146922054 1046 dbSNP
rs1465158430 1050 dbSNP
rs1026449608 1051 dbSNP
rs1421640062 1062 dbSNP
rs1433949182 1067 dbSNP
rs1266972716 1068 dbSNP
rs1189786879 1072 dbSNP
rs1459375353 1087 dbSNP
rs778490284 1095 dbSNP
rs747600067 1098 dbSNP
rs781977428 1147 dbSNP
rs532419021 1149 dbSNP
rs1249067251 1150 dbSNP
rs1234810560 1151 dbSNP
rs1331267372 1153 dbSNP
rs782250821 1177 dbSNP
rs1438434374 1178 dbSNP
rs948735661 1179 dbSNP
rs1378913225 1180 dbSNP
rs980487805 1194 dbSNP
rs1465076491 1197 dbSNP
rs1394288433 1206 dbSNP
rs926072261 1213 dbSNP
rs1466632302 1214 dbSNP
rs181873841 1216 dbSNP
rs1377218113 1220 dbSNP
rs936050619 1221 dbSNP
rs1441901247 1222 dbSNP
rs1239209128 1236 dbSNP
rs111922578 1237 dbSNP
rs1456787443 1240 dbSNP
rs1258888955 1242 dbSNP
rs1201606165 1249 dbSNP
rs1255039947 1255 dbSNP
rs1345193382 1255 dbSNP
rs1231690508 1256 dbSNP
rs1355546889 1258 dbSNP
rs1309664032 1267 dbSNP
rs892299384 1268 dbSNP
rs1445808433 1274 dbSNP
rs1333854935 1277 dbSNP
rs1336100138 1281 dbSNP
rs569007371 1282 dbSNP
rs1401644461 1283 dbSNP
rs531411683 1283 dbSNP
rs12204145 1284 dbSNP
rs1421705696 1284 dbSNP
rs1381172120 1300 dbSNP
rs890145325 1305 dbSNP
rs186396476 1317 dbSNP
rs1468927727 1326 dbSNP
rs1370696208 1327 dbSNP
rs1007243094 1330 dbSNP
rs1442476136 1332 dbSNP
rs41267937 1333 dbSNP
rs1208141823 1342 dbSNP
rs1489039352 1350 dbSNP
rs1286308410 1368 dbSNP
rs555890450 1369 dbSNP
rs1285871814 1371 dbSNP
rs1245479976 1393 dbSNP
rs532672226 1398 dbSNP
rs577606774 1400 dbSNP
rs1026523273 1401 dbSNP
rs1361336349 1408 dbSNP
rs1297888978 1410 dbSNP
rs1399307475 1413 dbSNP
rs950852447 1414 dbSNP
rs137891839 1422 dbSNP
rs149438731 1426 dbSNP
rs1416366129 1432 dbSNP
rs556582007 1434 dbSNP
rs544759930 1446 dbSNP
rs1263451338 1450 dbSNP
rs1214708561 1453 dbSNP
rs1445033016 1461 dbSNP
rs190353893 1462 dbSNP
rs183752542 1463 dbSNP
rs1355479345 1477 dbSNP
rs1220538152 1478 dbSNP
rs1291368560 1478 dbSNP
rs1341269276 1479 dbSNP
rs1277781425 1481 dbSNP
rs1428936435 1482 dbSNP
rs1333081550 1483 dbSNP
rs1324564071 1485 dbSNP
rs1405155452 1485 dbSNP
rs925907828 1485 dbSNP
rs936141189 1492 dbSNP
rs1173540869 1494 dbSNP
rs1466722343 1509 dbSNP
rs988849909 1521 dbSNP
rs1423782406 1522 dbSNP
rs1185458581 1524 dbSNP
rs1474193384 1526 dbSNP
rs143817668 1527 dbSNP
rs1199220222 1534 dbSNP
rs1467919781 1534 dbSNP
rs572183476 1536 dbSNP
rs746631475 1539 dbSNP
rs1271178237 1546 dbSNP
rs1200504313 1566 dbSNP
rs1318663366 1569 dbSNP
rs1272329015 1571 dbSNP
rs1212905186 1583 dbSNP
rs1369930863 1596 dbSNP
rs1275671994 1597 dbSNP
rs1436207303 1599 dbSNP
rs1369319666 1605 dbSNP
rs1333932363 1610 dbSNP
rs1448113711 1623 dbSNP
rs1400238465 1624 dbSNP
rs945196068 1626 dbSNP
rs1407716623 1630 dbSNP
rs1426823301 1637 dbSNP
rs1051521790 1640 dbSNP
rs1453550377 1645 dbSNP
rs782097347 1653 dbSNP
rs890388944 1656 dbSNP
rs1180311533 1661 dbSNP
rs1458120113 1662 dbSNP
rs1232250699 1667 dbSNP
rs1202447204 1695 dbSNP
rs1314089200 1704 dbSNP
rs782779250 1717 dbSNP
rs770241918 1736 dbSNP
rs943245597 1737 dbSNP
rs148151521 1748 dbSNP
rs1233911837 1755 dbSNP
rs1346134312 1759 dbSNP
rs1038697253 1764 dbSNP
rs781871210 1767 dbSNP
rs141924470 1768 dbSNP
rs187790695 1776 dbSNP
rs73739033 1778 dbSNP
rs1334367961 1783 dbSNP
rs1360437936 1783 dbSNP
rs1433672658 1788 dbSNP
rs1392903096 1791 dbSNP
rs886629572 1796 dbSNP
rs1440084646 1801 dbSNP
rs1407162317 1805 dbSNP
rs1175472072 1810 dbSNP
rs1484266873 1811 dbSNP
rs562652403 1825 dbSNP
rs1014445414 1834 dbSNP
rs1484778116 1835 dbSNP
rs1024444997 1839 dbSNP
rs1288429868 1839 dbSNP
rs1241317439 1840 dbSNP
rs370237666 1845 dbSNP
rs1316756442 1847 dbSNP
rs542857492 1853 dbSNP
rs1002192605 1856 dbSNP
rs764438985 1857 dbSNP
rs1413645285 1860 dbSNP
rs1373173944 1868 dbSNP
rs1299730185 1869 dbSNP
rs781955721 1872 dbSNP
rs1420070759 1878 dbSNP
rs1344441927 1880 dbSNP
rs1033050279 1888 dbSNP
rs957589669 1889 dbSNP
rs1425449087 1893 dbSNP
rs1414458414 1898 dbSNP
rs548401724 1907 dbSNP
rs1474304311 1915 dbSNP
rs1265590516 1916 dbSNP
rs782467515 1917 dbSNP
rs1485728485 1921 dbSNP
rs782615769 1930 dbSNP
rs955426225 1945 dbSNP
rs1224270535 1946 dbSNP
rs561123793 1952 dbSNP
rs1322787341 1953 dbSNP
rs1273116239 1957 dbSNP
rs1232148340 1960 dbSNP
rs1353088575 1963 dbSNP
rs1279677368 1988 dbSNP
rs146093493 1994 dbSNP
rs1360880971 2004 dbSNP
rs1286838744 2005 dbSNP
rs59837426 2007 dbSNP
rs1395116627 2013 dbSNP
rs1459248462 2013 dbSNP
rs1164193821 2014 dbSNP
rs527367231 2020 dbSNP
rs1459919663 2021 dbSNP
rs547192408 2022 dbSNP
rs1194516254 2048 dbSNP
rs943338345 2050 dbSNP
rs1259933300 2052 dbSNP
rs1193219746 2064 dbSNP
rs1489051153 2066 dbSNP
rs1252908473 2069 dbSNP
rs1212425133 2070 dbSNP
Experimental Support 1 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
Conditions HEK293
Disease 29777.0
Location of target site 3'UTR
Tools used in this research TargetScan , miRTarCLIP , Piranha
Original Description (Extracted from the article) ... "PAR-CLIP data was present in GSM714645. RNA binding protein: AGO2. Condition:completeT1 "PAR-CLIP data was present in GSM714647. RNA binding protein: AGO2. Condition:mildMNase ...

- Kishore S; Jaskiewicz L; Burger L; Hausser et al., 2011, Nature methods.

miRNA-target interactions (Provided by authors)
ID Duplex structure Position
1
miRNA  3' agcuGAC-GGU-GAGAAUGAucu 5'
              ||| |:| ||| ||||   
Target 5' cuucCUGUCUACCUCAUACU--- 3'
20 - 39
Article - Kishore S; Jaskiewicz L; Burger L; Hausser et al.
- Nature methods, 2011
Cross-linking and immunoprecipitation (CLIP) is increasingly used to map transcriptome-wide binding sites of RNA-binding proteins. We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites. We found only small differences in accuracies of these methods in identifying binding sites of HuR, which binds low-complexity sequences, and Argonaute 2, which has a complex binding specificity. We found that cross-link-induced mutations led to single-nucleotide resolution for both PAR-CLIP and CLIP. Our results confirm the expectation from original CLIP publications that RNA-binding proteins do not protect their binding sites sufficiently under the denaturing conditions used during the CLIP procedure, and we show that extensive digestion with sequence-specific RNases strongly biases the recovered binding sites. This bias can be substantially reduced by milder nuclease digestion conditions.
LinkOut: [PMID: 21572407]
Experimental Support 2 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
     
Conditions Hela
Location of target site 3'UTR
Tools used in this research TargetScan , miRTarCLIP , Piranha
Original Description (Extracted from the article) ... HITS-CLIP data was present in GSM1048187. RNA binding protein: AGO2. Condition:Hela_AGO2_CLIP_control ...

- Xue Y; Ouyang K; Huang J; Zhou Y; Ouyang H; et al., 2013, Cell.

Article - Xue Y; Ouyang K; Huang J; Zhou Y; Ouyang H; et al.
- Cell, 2013
The induction of pluripotency or trans-differentiation of one cell type to another can be accomplished with cell-lineage-specific transcription factors. Here, we report that repression of a single RNA binding polypyrimidine-tract-binding (PTB) protein, which occurs during normal brain development via the action of miR-124, is sufficient to induce trans-differentiation of fibroblasts into functional neurons. Besides its traditional role in regulated splicing, we show that PTB has a previously undocumented function in the regulation of microRNA functions, suppressing or enhancing microRNA targeting by competitive binding on target mRNA or altering local RNA secondary structure. A key event during neuronal induction is the relief of PTB-mediated blockage of microRNA action on multiple components of the REST complex, thereby derepressing a large array of neuronal genes, including miR-124 and multiple neuronal-specific transcription factors, in nonneuronal cells. This converts a negative feedback loop to a positive one to elicit cellular reprogramming to the neuronal lineage.
LinkOut: [PMID: 23313552]
Experimental Support 3 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
Conditions C8166
Location of target site 3'UTR
Tools used in this research TargetScan , miRTarCLIP , Piranha
Original Description (Extracted from the article) ... PAR-CLIP data was present in GSM1462572. RNA binding protein: AGO2. Condition:C8166 NL4-3 ...

- Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio.

Article - Whisnant AW; Bogerd HP; Flores O; Ho P; et al.
- mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
Experimental Support 4 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
Conditions MCF7
Location of target site 3'UTR
Tools used in this research TargetScan , miRTarCLIP , Piranha
Original Description (Extracted from the article) ... PAR-CLIP data was present in SRR1045082. RNA binding protein: AGO2. Condition:Untreated ...

- Farazi TA; Ten Hoeve JJ; Brown M; et al., 2014, Genome biology.

Article - Farazi TA; Ten Hoeve JJ; Brown M; et al.
- Genome biology, 2014
BACKGROUND: Various microRNAs (miRNAs) are up- or downregulated in tumors. However, the repression of cognate miRNA targets responsible for the phenotypic effects of this dysregulation in patients remains largely unexplored. To define miRNA targets and associated pathways, together with their relationship to outcome in breast cancer, we integrated patient-paired miRNA-mRNA expression data with a set of validated miRNA targets and pathway inference. RESULTS: To generate a biochemically-validated set of miRNA-binding sites, we performed argonaute-2 photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (AGO2-PAR-CLIP) in MCF7 cells. We then defined putative miRNA-target interactions using a computational model, which ranked and selected additional TargetScan-predicted interactions based on features of our AGO2-PAR-CLIP binding-site data. We subselected modeled interactions according to the abundance of their constituent miRNA and mRNA transcripts in tumors, and we took advantage of the variability of miRNA expression within molecular subtypes to detect miRNA repression. Interestingly, our data suggest that miRNA families control subtype-specific pathways; for example, miR-17, miR-19a, miR-25, and miR-200b show high miRNA regulatory activity in the triple-negative, basal-like subtype, whereas miR-22 and miR-24 do so in the HER2 subtype. An independent dataset validated our findings for miR-17 and miR-25, and showed a correlation between the expression levels of miR-182 targets and overall patient survival. Pathway analysis associated miR-17, miR-19a, and miR-200b with leukocyte transendothelial migration. CONCLUSIONS: We combined PAR-CLIP data with patient expression data to predict regulatory miRNAs, revealing potential therapeutic targets and prognostic markers in breast cancer.
LinkOut: [PMID: 24398324]
Experimental Support 5 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
Conditions Prostate Tissue
Location of target site 3'UTR
Tools used in this research TargetScan , miRTarCLIP , Piranha
Original Description (Extracted from the article) ... PAR-CLIP data was present in SRX1760583. RNA binding protein: AGO2. Condition:AGO-CLIP-LNCaP_A PAR-CLIP data was present in SRX1760639. RNA binding protein: AGO2. Condition:AGO-CLIP-LNCaP-MDV_A ...

- Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al., 2016, Neoplasia (New York, N.Y.).

Article - Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al.
- Neoplasia (New York, N.Y.), 2016
MicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and metastatic progression. To comprehensively define the cancer-associated changes in miRNA targeting and function in commonly studied models of PCa, we performed photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of the Argonaute protein in a panel of PCa cell lines modeling different stages of PCa progression. Using this comprehensive catalogue of miRNA targets, we analyzed miRNA targeting on known drivers of PCa and examined tissue-specific and stage-specific pathway targeting by miRNAs. We found that androgen receptor is the most frequently targeted PCa oncogene and that miR-148a targets the largest number of known PCa drivers. Globally, tissue-specific and stage-specific changes in miRNA targeting are driven by homeostatic response to active oncogenic pathways. Our findings indicate that, even in advanced PCa, the miRNA pool adapts to regulate continuing alterations in the cancer genome to balance oncogenic molecular changes. These findings are important because they are the first to globally characterize miRNA changes in PCa and demonstrate how the miRNA target spectrum responds to staged tumorigenesis.
LinkOut: [PMID: 27292025]
CLIP-seq Support 1 for dataset GSM1048187
Method / RBP HITS-CLIP / AGO2
Cell line / Condition Hela / Hela_AGO2_CLIP_control
Location of target site ENST00000274849.1 | 3UTR | CAUUUCCUGGCCCUGCUCUGCUUCCUGUCUACCUCAUA
Tools used in this analysis TargetScan, miRTarCLIP, and Piranha
Article / Accession Series PMID: 23313552 / GSE42701
CLIP-seq Viewer Link
CLIP-seq Support 2 for dataset GSM714645
Method / RBP PAR-CLIP / AGO2
Cell line / Condition HEK293 / completeT1, repB
Location of target site ENST00000274849.1 | 3UTR | CUCUGCUUCCUGUCUACCUCAUACUAG
Tools used in this analysis TargetScan, miRTarCLIP, and Piranha
Article / Accession Series PMID: 21572407 / GSE28865
CLIP-seq Viewer Link
CLIP-seq Support 3 for dataset GSM714647
Method / RBP PAR-CLIP / AGO2
Cell line / Condition HEK293 / mildMNase, repB
Location of target site ENST00000274849.1 | 3UTR | AUUUCCUGGCCCUGCUCUGCUUCCUGUCUACCUCAUACU
Tools used in this analysis TargetScan, miRTarCLIP, and Piranha
Article / Accession Series PMID: 21572407 / GSE28865
CLIP-seq Viewer Link
CLIP-seq Support 4 for dataset SRR1045082
Method / RBP PAR-CLIP / AGO2
Cell line / Condition MCF7 / Untreated
Location of target site ENST00000274849.1 | 3UTR | CCCUGCUCUGCUUCCUGUCUACCUCAUACUAG
Tools used in this analysis TargetScan, miRTarCLIP, and Piranha
Article / Accession Series PMID: 24398324 / SRX388831
CLIP-seq Viewer Link
CLIP-seq Support 5 for dataset GSM1462572
Method / RBP PAR-CLIP / AGO2
Cell line / Condition C8166 / C8166 NL4-3
Location of target site ENST00000274849.1 | 3UTR | CCCUGCUCUGCUUCCUGUCUACCUCAUACUAG
Tools used in this analysis TargetScan, miRTarCLIP, and Piranha
Article / Accession Series PMID: 23592263 / GSE59944
CLIP-seq Viewer Link
MiRNA-Target Expression Profile
Dataset Pearson Correlation P-value for Pearson Correlation Spearman Correlation P-value for Spearman Correlation Samples Chart
GSE34608 Pulmonary tuberculosis and sarcoidosis 0.539 7.1e-3 0.568 4.5e-3 20 Click to see details
GSE27834 Pluripotent stem cells 0.569 1.1e-2 0.532 1.7e-2 16 Click to see details
GSE28544 Breast cancer -0.461 1.2e-2 -0.472 9.9e-3 24 Click to see details
GSE42095 Differentiated embryonic stem cells -0.371 4.1e-2 -0.375 3.9e-2 23 Click to see details
GSE17306 Multiple myeloma 0.2 8.4e-2 0.139 1.7e-1 49 Click to see details
GSE28260 Renal cortex and medulla 0.389 9.4e-2 0.363 1.1e-1 13 Click to see details
GSE21849 B cell lymphoma -0.231 1.1e-1 -0.158 2.1e-1 29 Click to see details
GSE19783 ER- ER- breast cancer 0.127 1.3e-1 0.049 3.3e-1 79 Click to see details
GSE21687 Ependynoma primary tumors -0.131 1.5e-1 -0.093 2.3e-1 64 Click to see details
GSE38974 Chronic obstructive pulmonary disease -0.208 1.6e-1 -0.305 6.9e-2 25 Click to see details
GSE19783 ER+ ER+ breast cancer -0.16 2.5e-1 -0.176 2.3e-1 20 Click to see details
GSE19536 Breast cancer 0.065 2.6e-1 0.032 3.8e-1 100 Click to see details
GSE19350 CNS germ cell tumors 0.196 2.7e-1 0.238 2.3e-1 12 Click to see details
GSE17498 Multiple myeloma 0.085 3.0e-1 -0.044 3.9e-1 40 Click to see details
GSE14794 Lymphoblastoid cells 0.036 3.7e-1 0.024 4.1e-1 90 Click to see details
GSE38226 Liver fibrosis 0.057 4.0e-1 -0.192 2.0e-1 21 Click to see details
GSE26953 Aortic valvular endothelial cells -0.048 4.1e-1 -0.111 3.0e-1 24 Click to see details
GSE32688 Pancreatic cancer -0.026 4.4e-1 0.083 3.3e-1 32 Click to see details
GSE32688 Pancreatic cancer -0.026 4.4e-1 0.083 3.3e-1 32 Click to see details
GSE32688 Pancreatic cancer -0.026 4.4e-1 0.083 3.3e-1 32 Click to see details
MiRNA-Target Expression Profile (TCGA)
Tumor Pearson Correlation P-value for Pearson Correlation Spearman Correlation P-value for Spearman Correlation Samples Chart
HNSC -0.344 0.02 -0.374 0.01 35 Click to see details
ESCA 0.566 0.03 0.682 0.01 11 Click to see details
KIRC -0.256 0.06 -0.304 0.03 40 Click to see details
LUSC 0.256 0.07 0.242 0.08 35 Click to see details
KICH -0.323 0.07 -0.280 0.1 22 Click to see details
PRAD 0.21 0.11 0.291 0.04 36 Click to see details
BLCA 0.274 0.14 0.360 0.08 17 Click to see details
PAAD 0.688 0.16 0.800 0.1 4 Click to see details
LIHC 0.141 0.17 0.108 0.23 49 Click to see details
KIRP 0.183 0.17 0.188 0.16 29 Click to see details
BRCA 0.148 0.2 0.084 0.32 34 Click to see details
STAD 0.155 0.22 0.131 0.25 28 Click to see details
PCPG -0.595 0.3 -0.500 0.33 3 Click to see details
LUAD -0.191 0.3 -0.236 0.26 10 Click to see details
CHOL 0.171 0.36 0.214 0.32 7 Click to see details
THCA 0.029 0.41 0.062 0.32 58 Click to see details
UCEC 0.023 0.46 -0.009 0.49 18 Click to see details
CESC -0.011 0.5 0.500 0.33 3 Click to see details
CESC -0.011 0.5 0.500 0.33 3 Click to see details
27 hsa-miR-628-3p Target Genes:
Functional analysis:
ID Target Description Validation methods
Strong evidence Less strong evidence
MIRT039584 CDC14A cell division cycle 14A 1 1
MIRT039585 AGO1 argonaute 1, RISC catalytic component 2 3
MIRT039586 TGFBRAP1 transforming growth factor beta receptor associated protein 1 1 1
MIRT039587 LRP6 LDL receptor related protein 6 1 1
MIRT071876 BTF3L4 basic transcription factor 3 like 4 2 2
MIRT097443 JMY junction mediating and regulatory protein, p53 cofactor 2 4
MIRT100100 ABT1 activator of basal transcription 1 2 8
MIRT147692 CBX4 chromobox 4 2 2
MIRT408248 PURA purine rich element binding protein A 2 2
MIRT442047 LRAT lecithin retinol acyltransferase 2 2
MIRT444412 RAB3IP RAB3A interacting protein 2 2
MIRT452599 REPIN1 replication initiator 1 2 2
MIRT469515 RBFOX2 RNA binding protein, fox-1 homolog 2 2 8
MIRT498192 AKR1B10 aldo-keto reductase family 1 member B10 2 2
MIRT500151 CREBBP CREB binding protein 2 2
MIRT507319 FAM60A SIN3-HDAC complex associated factor 2 6
MIRT508343 ZNF273 zinc finger protein 273 2 6
MIRT520480 TRIM13 tripartite motif containing 13 2 2
MIRT522461 MMP16 matrix metallopeptidase 16 2 4
MIRT547116 PHLPP2 PH domain and leucine rich repeat protein phosphatase 2 2 2
MIRT548675 CRNKL1 crooked neck pre-mRNA splicing factor 1 2 2
MIRT553756 TARBP2 TARBP2, RISC loading complex RNA binding subunit 2 4
MIRT559437 ARSJ arylsulfatase family member J 2 2
MIRT610490 GPC4 glypican 4 2 2
MIRT644682 TMCO1 transmembrane and coiled-coil domains 1 2 2
MIRT658214 FBXO21 F-box protein 21 2 2
MIRT756083 TP53 tumor protein p53 4 1
miRNA-Drug Resistance Associations
miRNA Drug Name CID NSC FDA Effect/Pattern Detection Method Level Phenotype Condition
hsa-mir-628 Cisplatin 5460033 NSC119875 approved sensitive cell line (BxPC3)
hsa-miR-628-3p Cisplatin 5460033 NSC119875 approved resistant High Tongue Squamous Cell Carcinoma cell line (Tca8113)
hsa-miR-628-3p Tamoxifen 2733525 NSC180973 approved resistant High Breast Cancer cell line (MCF-7, LY2)
hsa-miR-628-3p Erlotinib 176870 NSC718781 approved sensitive High Epithelial Cancer cell line (A549, UKY-29, H460, H1975, H1650, H3255, PC-9, H358)
hsa-miR-628-3p Siop Treatment Protocol sensitive High Nephroblastoma tissue
hsa-miR-628-3p Sunitinib 5329102 NSC750690 approved resistant High Metastatic Renal Cell Carcinoma tissue and cell line (Caki-2)
hsa-miR-628-3p Chemotherapy sensitive High Epithelial Ovarian Cancer tissue
hsa-miR-628-3p Platinum-based doublet chemotherapy resistant Low Lung Adenocarcinoma tissue
hsa-miR-628-3p Doxorubicin 31703 NSC123127 approved sensitive High Gastric Cancer cell line (SGC7901)
hsa-miR-628-3p Tamoxifen 2733525 NSC180973 approved resistant High Breast Cancer cell line (TAMR8)
hsa-miR-628-3p Aromatase Inhibitor sensitive Low Breast Cancer cell line (MCF-7)
hsa-miR-628-3p Dabrafenib 44462760 NSC764134 approved resistant High Melanoma cell line (A375, IGR37, 501Mel)
hsa-miR-628-3p Vemurafenib 42611257 NSC761431 approved resistant High Melanoma cell line (A375, IGR37, 501Mel)
hsa-miR-628-3p Ceritinib 57379345 NSC776422 approved sensitive High Non-Small Cell Lung Cancer cell line (H3122, H2228)
hsa-miR-628-3p Platinum 23939 sensitive High High-Grade Serous Ovarian Cancer tissue
hsa-miR-628-3p Cisplatin 5460033 NSC119875 approved sensitive High Bladder Cancer cell line (CDDP-R-BOY, CDDP-R-T24)
hsa-miR-628-3p Gefitinib 123631 NSC715055 approved resistant cell line (HCC827)
hsa-miR-628-3p Gefitinib 123631 NSC715055 approved sensitive cell line (HCC827)
hsa-miR-628-3p Fluorouracil 3385 NSC19893 approved resistant cell line (KM12C) (72 h)
hsa-miR-628-3p Sunitinib 5329102 NSC750690 approved resistant tissue (CardB)
hsa-miR-628-3p Tamoxifen 2733525 NSC180973 approved resistant cell line (TamR8)
hsa-miR-628-3p Oxaliplatin 6857599 NSC266046 approved sensitive cell line (IGROV-1)
hsa-miR-628-3p Cisplatin 5460033 NSC119875 approved sensitive cell line (A549)
hsa-miR-628-3p Gemcitabine 60750 NSC613327 approved sensitive cell line (PANC-1) (1500 ng/ml)
hsa-miR-628-3p Docetaxel+Cisplatin+5-Fluorouracil sensitive tissue (hypopharyngeal squamous cell carcinoma)

Error report submission